| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 保肝护肝药物(元) | - | 202,699,400.74 | 88,076,904.70 | 177,898,496.50 | 84,177,925.75 |
| 呼吸系统药物(元) | 28,037,950.15 | 3,092,057.19 | 1,572,878.01 | 3,300,370.24 | 1,577,052.20 |
| 抗乙肝病毒药物(元) | - | 121,682,100.06 | 59,059,553.04 | 155,086,552.88 | 78,781,443.84 |
| 男性健康产品(元) | - | 10,418,603.75 | -1,186,349.79 | 2,512,444.51 | 1,138,898.41 |
| 消化系统药物(元) | - | 18,881,922.26 | 9,526,290.10 | 18,465,953.85 | 9,570,442.91 |
| 心血管药物(元) | 22,560,526.93 | 35,572,196.34 | 14,504,252.71 | 22,494,248.38 | 10,773,254.61 |
| 抗新冠病毒药物(元) | - | 20,971,308.85 | - | - | - |
| 肝胆疾病药物(元) | 144,345,212.07 | - | - | - | - |
| 其他(元) | - | - | - | 6,007,118.37 | - |
| 营业成本(元) | |||||
| 保肝护肝药物(元) | - | 39,956,874.90 | 17,222,393.60 | 36,067,940.55 | - |
| 呼吸系统药物(元) | 13,651,550.51 | - | - | - | - |
| 抗乙肝病毒药物(元) | - | 70,492,855.43 | 33,896,299.26 | 84,697,770.37 | - |
| 男性健康产品(元) | - | - | - | - | - |
| 消化系统药物(元) | - | - | - | - | - |
| 心血管药物(元) | 7,089,806.86 | - | - | - | - |
| 抗新冠病毒药物(元) | - | - | - | - | - |
| 肝胆疾病药物(元) | 45,045,544.39 | - | - | - | - |
| 其他(元) | - | - | - | 3,883,080.76 | - |
| 毛利(元) | |||||
| 保肝护肝药物(元) | - | 162,742,525.84 | 70,854,511.10 | 141,830,555.95 | - |
| 呼吸系统药物(元) | 14,386,399.64 | - | - | - | - |
| 抗乙肝病毒药物(元) | - | 51,189,244.63 | 25,163,253.78 | 70,388,782.51 | - |
| 男性健康产品(元) | - | - | - | - | - |
| 消化系统药物(元) | - | - | - | - | - |
| 心血管药物(元) | 15,470,720.07 | - | - | - | - |
| 抗新冠病毒药物(元) | - | - | - | - | - |
| 肝胆疾病药物(元) | 99,299,667.68 | - | - | - | - |
| 其他(元) | - | - | - | 2,124,037.61 | - |
| 毛利率(%) | |||||
| 保肝护肝药物(%) | - | 80.29 | 80.45 | 79.73 | - |
| 呼吸系统药物(%) | 51.31 | - | - | - | - |
| 抗乙肝病毒药物(%) | - | 42.07 | 42.61 | 45.39 | - |
| 男性健康产品(%) | - | - | - | - | - |
| 消化系统药物(%) | - | - | - | - | - |
| 心血管药物(%) | 68.57 | - | - | - | - |
| 抗新冠病毒药物(%) | - | - | - | - | - |
| 肝胆疾病药物(%) | 68.79 | - | - | - | - |
| 其他(%) | - | - | - | 35.36 | - |
| 收入构成(%) | |||||
| 保肝护肝药物(%) | - | 49.04 | 51.34 | 46.12 | 45.25 |
| 呼吸系统药物(%) | 14.38 | 0.75 | 0.92 | 0.86 | 0.85 |
| 抗乙肝病毒药物(%) | - | 29.44 | 34.43 | 40.20 | 42.35 |
| 男性健康产品(%) | - | 2.52 | -0.69 | 0.65 | 0.61 |
| 消化系统药物(%) | - | 4.57 | 5.55 | 4.79 | 5.14 |
| 心血管药物(%) | 11.57 | 8.61 | 8.45 | 5.83 | 5.79 |
| 抗新冠病毒药物(%) | - | 5.07 | - | - | - |
| 肝胆疾病药物(%) | 74.04 | - | - | - | - |
| 其他(%) | - | - | - | 1.56 | - |
| 毛利构成(%) | |||||
| 保肝护肝药物(%) | - | 76.07 | 73.79 | 66.17 | - |
| 呼吸系统药物(%) | 11.14 | 0.00 | 0.00 | 0.00 | - |
| 抗乙肝病毒药物(%) | - | 23.93 | 26.21 | 32.84 | - |
| 男性健康产品(%) | - | 0.00 | 0.00 | 0.00 | - |
| 消化系统药物(%) | - | 0.00 | 0.00 | 0.00 | - |
| 心血管药物(%) | 11.98 | 0.00 | 0.00 | 0.00 | - |
| 抗新冠病毒药物(%) | - | 0.00 | - | - | - |
| 肝胆疾病药物(%) | 76.88 | - | - | - | - |
| 其他(%) | - | - | - | 0.99 | - |